The FDA approved AbbVie's once-daily Parkinson's pill tavapadon, branded as Juvmo, following a late-stage study. Meanwhile, Novo Nordisk is increasingly marketing Wegovy for direct-to-consumer weight loss rather than chronic obesity treatment, with cash-paying patients spending up to $450 monthly, r